-transparent.png){kind=logo}
Thirty-nine patients with metastatic prostate cancer refractory to hormonal manipulation were treated with vinblastine by continuous infusion. The dose was 1.5 mg/m2 daily for 5 days. A 21% response rate was obtained. Eight patients, two with visceral metastasis, one with nodal disease, and five with osseous metastasis achieved objective response. The median duration of response was 28 weeks. Myelosuppression was the major side effect: the median leukocyte count nadir was 2.8 X 10(3)/ml and the median platelet count nadir was 184 X 10(3)/ml.
Related Publications
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
August 1988,
American journal of clinical oncology,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
December 1999,
Urology,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
January 1980,
Cancer treatment reports,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
September 1993,
Cancer,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
March 1994,
Cancer,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
May 1987,
Cancer treatment reports,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
January 2005,
Anticancer research,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
February 2008,
Clinical advances in hematology & oncology : H&O,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
February 1987,
Gynecologic oncology,
F Dexeus, and
C J Logothetis, and
M L Samuels, and
E Hossan, and
A C von Eschenbach
October 1982,
American journal of clinical oncology,
